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and short review of the literature
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Background: Cystoid macular edema (CME) in retinitis pigmentosa (RP) has been managed in several ways as
documented in the literature, with little success, though. The aim of our study was to report for the first time in
literature the use of aflibercept in a patient with RP and CME.
Case presentation: A 52-year-old man presented for blurred vision in his right eye. Best-corrected visual acuity
(BCVA) was 3/10 in his right eye and 7/10 in his left eye. Physical examination and appropriate laboratory tests lead
to the diagnosis of bilateral RP with CME in the right eye. Retinal thickness in the foveal area of the right eye was
631 μm. The patient was treated with a single intravitreal injection of 0.05 ml/0.5 mg aflibercept. One month later,
BCVA of the right eye increased to 4/10, while BCVA of the left eye was unchanged. RT in the right eye decreased
to 129 μm. Multifocal electroretinogram response did not improve, yet peaks were better-shaped and no areas of
eccentral vision were present. Three and six months after injection, these improvements were maintained.
Conclusion: This first-reported case indicates that intravitreal aflibercept injection for addressing CME in RP seems
to be an effective treatment.
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Retinitis pigmentosa (RP) is a group of inherited de-
generative retinal disorders characterized by loss of
photoreceptors (rods predominantly) and dystrophy of
the pigment epithelium [1]. Visual acuity in RP pa-
tients is mostly deteriorated in the presence of cystoid
macular edema (CME), an uncommon complication of
the disease occurring in 10-20% of patients [2]. The
pathogenesis of CME in RP is not clearly understood.
Failure of the retinal pigment epithelium pumping
mechanism and compromise of the blood-retinal barrier
has been implicated [3,4]. Increased vascular permeability
allows for fluid to accumulate in cystoid spaces within the
retina [5].* Correspondence: moschosmarilita@yahoo.fr
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unless otherwise stated.Currently, there is no effective treatment suspending
or reversing photoreceptor degeneration, yet complica-
tions, such as CME, have been managed in different
ways. Some of the treatments that have been tested on
CME in RP are systemic or topical carbonic anhydrase
inhibitors (acetazolamide and dorzolamide, respectively),
systemic or intravitreal (triamcinolone, dexamethasone)
corticosteroids, laser photocoagulation and pars plana
vitrectomy [2,4,6-21]. Some cohorts show favorable re-
sults with oral acetazolamide therapy achieving an in-
crease in best-corrected visual acuity (BCVA), decrease
in vascular leakage as seen with fluorescein angiography
and decrease in retinal thickness [4,6-8]. Other studies
failed to generate similar results [9,10], and indeed, in
clinical practice, many are the patients who do not re-
spond to this kind of treatment [22,23]. These unstable
results in conjunction with the adverse effects of acet-
azolamide administration are the main reasons for whichn Access article distributed under the terms of the Creative Commons
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Figure 2 Fundoscopy showing peripheral bone-spicule-like
pigmentations and arterial narrowing characteristic of retinitis pigmentosa.
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sary. Only selected patients are benefited by intravitreal
triamcinolone injection (IVT) and results seem to be
short-lasting [2,15,16]. IVT may also cause glaucoma,
cataract, infectious endophthalmitis and retinal detach-
ment [16].
During the last seven years, attention has been given to
the inhibition of the vascular endothelial growth factor
(VEGF), when CME is present secondary to RP, which is
known to promote endothelial cell mitosis and increase
vascular permeability, resulting in edema [24].
In the context of these report studies with VEGF inhibi-
tors for the management of CME associated with RP, we
present for the first time in the literature a case of RP with
CME treated with the anti-VEGF agent aflibercept
(EYLEA; Regeneron Pharmaceuticals, Inc., Tarrytown,
New York, USA and Bayer Healthcare Pharmaceuticals,
Berlin, Germany).
Case presentation
A 52-year-old caucasian man (Figure 1) with no remark-
able past medical and family history was referred to the
First Department of Ophthalmology, University of Athens,
Greece complaining for blurred vision in his right eye.
Upon examination, BCVA was 7/10 in his left eye and
3/10 in his right eye. Fundoscopy of the left eye re-
vealed mid-peripheral hyperpigmentary spots in form of
bone-spicules and arteriolar narrowing, while in the right
eye clinical findings were similar (Figure 2). Appropriate
visual field tests, OCT and multifocal electroretinogram
(mfERG) [25] were performed and, eventually, the patient
was diagnosed with RP and CME of the right eye. OCT
(Spectralis®, Track Laser Tomography) was performed to
evaluate the macular edema. In addition to this, mfERG
was performed to assess retinal function. OCT scan
showed intraretinal fluid and a significant increase in
retinal thickness in the foveal (631 μm) area (Figure 3).
Moreover, mfERG showed decreased response in both
eyes. The mean P1 retinal response density (RRD) ampli-
tude of the foveal area was 86 nV/deg2 in right eye and
106 nV/deg2 in left eye (Figure 4).
Due to the controversial results of most therapeutic
options for CME in RP (carbonic anhydrase inhibitors,
corticosteroids), the patient was consulted to be treated
with a VEGF inhibitor. He was informed about the off-Figure 1 Timeline of events for the presented case.label therapy and signed a written consent prior to ther-
apy initiation. The VEGF inhibitor selected was afliber-
cept, due to its binding not only to the VEGF-A isomers
(like bevacizumab and ranibizumab), but also to VEGF-
B and placental growth factor [26]. Moreover, its longer
duration of action and its powerful VEGF binding were
additional factors that led to its selection [27]. A single
injection of 0.05 ml/0.5 mg aflibercept (EYLEA; Regen-
eron Pharmaceuticals, Inc., Tarrytown, New York, USA
and Bayer Healthcare Pharmaceuticals, Berlin, Germany)
was performed to treat macular edema. One month after
treatment, BCVA in the right eye elevated to 4/10 and
macular edema had apparently improved, as it is
depicted in the respective OCT scan (Figure 3). BCVA of
the left eye was unchanged. Nevertheless, mfERG re-
sponse remained decreased in both eyes (87 nV/deg2 in
right eye and 106 nV/deg2 in left eye). It is worthy to say
that even if the RRD remained decreased, the mfERG
peaks were better shaped and there were not areas of
eccentral vision in the one-month follow-up (Figure 4).
The patient was also seen two months later (three
months after treatment) with BCVA in his right eye still
Figure 3 OCT scans of the right eye at presentation (A) and one month after intravitreal aflibercept (B) with macular thickness measuring
631 μm and 129 μm, respectively.
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last visit, six months after treatment, the improvement
was maintained. No other drugs were co-administered
and the patient did not receive any other kind of therapy
for his condition.
Discussion
CME is a complication of RP occurring in 10-20% of pa-
tients [2]. Currently there is not a gold-standard thera-
peutic option and treatment response seems to be
individualized. Many caregivers deem carbonic anhy-
drase inhibitors to be the mainstay of treatment. Yet,
many are the patients who fail to respond to carbonic
anhydrase inhibitors therapy [9,10,22,23]. Additionally,
considering their adverse effects, their use is discour-
aged. The same is true for IVT [2,15,16]. During the last
few years, a limited amount of studies have tested VEGF
inhibitors in the management of CME secondary to RP
with generally good results [22,23,28]. In 2007, Melo
et al. [29], presented two eyes of two different cases, in
which intravitreal bevacizumab (AVASTIN; Genentech,
South San Francisco, California, USA) was tested. The
first patient failed to achieve an increase in visual acuity
(VA, 2/200 pre- and post-injection) or decrease in ret-
inal thickness (524 μm and 529 μm pre- and post-
injection, respectively) after follow-up of one month,
while in the second patient VA deteriorated from 2/100
to 2/200 and retinal thickness increased from 282 μm to
299 μm one month after the injection. Both patients
showed ambiguous improvement with IVT. However, in
2009, Yuzbasioglu et al. [28] followed 13 eyes of 7 pa-
tients treated with intravitreal bevacizumab for a period
of 10.3 months. VA increased from 5/400-20/100 to 20/200-20/63 and central macular thickness decreased from
245–603 μm to 124–168 μm. Other anti-VEGF agents
have also been tested in CME secondary to RP, such as
pegaptanib sodium (MACUGEN; EyeTech Pharmaceut-
ical, Inc., New York, USA); particularly, Querques et al.
[22] presented a case refractory to oral acetazolamide
(1 month, 500 mg daily) with baseline BCVA 2/200 in
his left eye (the one with the CME). One dose of intra-
vitreal pegaptanib sodium 0.3 mg lead to improvement
in BCVA to 20/40 and resolution of CME as seen with
fundus microscopy and optical coherence tomography
(OCT). Oral acetazolamide was continued for an add-
itional month, and two months after acetazolamide with-
drawal and 4 months after the pegaptanic sodium
injection, BCVA still maintained at 20/40 and no recur-
rence of the CME was noticed. A cohort study reporting
on the use of anti-VEGF agents in CME-RP was con-
ducted in 2009 by Artunay et al. [23], who used intravit-
real ranibizumab (LUCENTIS; Genentech, South San
Francisco, California, USA) in 15 eyes of 15 patients
with persistent edema at least 6 months despite acetazol-
amide therapy. 15 eyes of 15 similar patients who re-
fused this off-label treatment were considered the
control group. 6 months after one dose of intravitreal
ranbizumab 0.5 mg, both central foveal thickness and
BCVA showed improvement, although improvement of
BCVA was not statistically significant (p > 0.05). How-
ever, none of the studies above used aflibercept for this
condition and none of the studies used multifocal-
electroretinogram to assess retinal function.
Aflibercept is a chimeric protein consisted of the
extracellular portion of the human VEGF receptors 1
and 2 (binding section) and the Fc portion of IgG1
Figure 4 3D appearance of mfERG recording and mfERG traces on the right eye at presentation (A,B) and one month after the intravitreal
aflibercept (C,D).
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VEGF binding affinity [27]. Furthermore, its long dur-
ation of action makes it an interesting new agent, since
it may reduce frequency of repeat injections if needed,
and establish a more durable effect [26,27]. Most fre-
quent adverse reactions (≥5%) that have been observed
with intravitreal aflibercept injection are conjunctival
hemorrhage, eye pain, cataract, vitreous floaters, and
transiently increased intraocular pressure [31]. Severeadverse events, such as endophthalmitis and retinal de-
tachment are rare (<0.1%) [31]. Currently, aflibercept
has been approved by the US Food and Drug Adminis-
tration (FDA) for the management of neovascular (wet)
age-related macular degeneration (2011), diabetic macu-
lar edema (2014) and macular edema following retinal
vein occlusion (2014). No testing has been made on
macular edema associated with RP and this case report
is the first clue of efficacy of aflibercept. Our patient
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resolution of macular edema in OCT scan, although
mfERG response remained decreased (yet, better-shaped
peaks and no areas of eccentral vision).
Our results show that there are anatomical correlates
to support the concept of macular edema amelioration.
This is mainly the prominent decrease of macular thick-
ness as measured by OCT. The mean visual acuity im-
proved only by 10% one month after treatment and
remained unchanged two months later. On the contrary,
mfERG findings did not follow the decrease of macular
thickness. These findings show that the increase of vis-
ual acuity, as also the improvement of electrical re-
sponses of the macular area did not follow the decrease
of macular thickness. This may be explained by the fact
that macular edema is only a parameter that may affect
visual acuity and electrophysiological responses in the
beginning of the disease. Atrophy of the retina, particu-
larly of the photoreceptors, atrophy of the pigment epi-
thelium and scarring are all unmeasured variables,
which have potential to impact vision. Of course, we are
not able to definitely conclude on the issue, merely
based on this case and further studies with larger sam-
ples and a longer follow-up period are needed for this
reason. However the anatomical improvement is very
promising and further investigation must be done.
Conclusion
Intravitreal aflibercept injection treatment seems to be
efficacious for addressing CME secondary to RP. Add-
itional studies are needed to confirm the aforemen-
tioned result.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
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